# Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct03032965` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03032965](<https://clinicaltrials.gov/study/NCT03032965>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03032965

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.

## Technical summary

Registry record NCT03032965. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-07 (actual). Results posted on 2017-12-13.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 131 participants (enrolled count; ClinicalTrials.gov record NCT03032965, source copy `cardio:ctgov-nct03032965-2017-12-13`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT03032965, source copy `cardio:ctgov-nct03032965-2017-12-13`, retrieved 2026-10-26)
- Primary completion: 2015-07 (actual) (ClinicalTrials.gov record NCT03032965, source copy `cardio:ctgov-nct03032965-2017-12-13`, retrieved 2026-10-26)
- Completion: 2015-07 (actual) (ClinicalTrials.gov record NCT03032965, source copy `cardio:ctgov-nct03032965-2017-12-13`, retrieved 2026-10-26)
- Results first posted: 2017-12-13 (ClinicalTrials.gov record NCT03032965, source copy `cardio:ctgov-nct03032965-2017-12-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03032965, source copy `cardio:ctgov-nct03032965-2017-12-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03032965-2017-12-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Drug): Adenosine
- Intervention (Drug): Isoproterenol
- Lead sponsor: University of Michigan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: University of Michigan (`cardio:org-university-of-michigan`)

## Provenance

Content hash: f7f4f3a60eb214a84344032984c06b0e85e3b005f7b22b8df84c62ff1d90d72d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
